UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
SCHEDULE 13G
Under the Securities Exchange Act of 1934
(Amendment No. 7)*
Arch Therapeutics, Inc.
(Name of Issuer)
Common Stock, par value $0.001 per share
(Title of Class of Securities)
003939W 109
(CUSIP Number)
Michael Parker
1928 East Highland Avenue, Suite F104-558
Phoenix, Arizona 85016
(480) 717-0911
(Name, Address and Telephone Number of Person
Authorized to Receive Notices and Communications)
December 31, 2020
(Date of Event which Requires Filing of this Statement)
Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
☐ Rule 13d-1(b)
x Rule 13d-1(c)
☐ Rule 13d-1(d)
* The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page.
The information required on the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).
CUSIP No. 003939W 109 | SCHEDULE 13G | Page 2 of 8 Pages |
1.NAMES OF REPORTING PERSONS
Michael Parker
2.CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (see instructions)
(a) x
(b) ☐
3.SEC USE ONLY
4.CITIZENSHIP OR PLACE OF ORGANIZATION
United States
NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH
5.SOLE VOTING POWER
6,380,891 shares of Common Stock (see Appendix A)
6.SHARED VOTING POWER
9,086,939 shares of Common Stock (see Appendix A)
7.SOLE DISPOSITIVE POWER
6,380,891 shares of Common Stock (see Appendix A)
8.SHARED DISPOSITIVE POWER
9,086,939 shares of Common Stock (see Appendix A)
9.AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
15,467,830 shares of Common Stock (see Appendix A)
10.CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (see instructions)
x
11.PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)
8.01% (see Appendix A)
12.TYPE OF REPORTING PERSON (see instructions)
IN
CUSIP No. 003939W 109 | SCHEDULE 13G | Page 3 of 8 Pages |
1.NAMES OF REPORTING PERSONS
Ana Parker
2.CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (see instructions)
(a) x
(b) ☐
3.SEC USE ONLY
4.CITIZENSHIP OR PLACE OF ORGANIZATION
United States
NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH
5.SOLE VOTING POWER
N/A
6.SHARED VOTING POWER
9,086,939 (see Appendix A)
7.SOLE DISPOSITIVE POWER
N/A
8.SHARED DISPOSITIVE POWER
9,086,939 (see Appendix A)
9.AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
9,086,939 shares of Common Stock (see Appendix A)
10.CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (see instructions)
x
11.PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)
4.71% (see Appendix A)
12.TYPE OF REPORTING PERSON (see instructions)
IN
CUSIP No. 003939W 109 | SCHEDULE 13G | Page 4 of 8 Pages |
Item 1.
(a)Name of Issuer
Arch Therapeutics, Inc.
(b)Address of Issuer's Principal Executive Offices
235 Walnut Street, Suite 6, Framingham, MA 01702
Item 2.
(a)Name of Person Filing
This Statement is filed by Michael Parker and Ana Parker. Michael Parker and Ana Parker are married.
(b)Address of the Principal Office or, if none, residence
Each Reporting Person’s address is 1928 East Highland Avenue, Suite F104-558, Phoenix, Arizona 85016
(c)Citizenship
Each Reporting Person is a citizen of the United States.
(d)Title of Class of Securities
Common Stock, par value $0.001 per share
(e)CUSIP Number
003939W 109
Item 3. If this statement is filed pursuant to §§240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
(a)Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o).
(b)Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c).
(c)Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c).
(d)Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8).
(e)An investment adviser in accordance with §240.13d-1(b)(1)(ii)(E);
(f)An employee benefit plan or endowment fund in accordance with §240.13d-1(b)(1)(ii)(F);
(g)A parent holding company or control person in accordance with §240.13d-1(b)(1)(ii)(G);
(h)A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
(i)A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
(j)Group, in accordance with §240.13d-1(b)(1)(ii)(J).
CUSIP No. 003939W 109 | SCHEDULE 13G | Page 5 of 8 Pages |
Item 4. Ownership.
Provide the following information regarding the aggregate number and percentage of the class of securities of the issuer identified in Item 1.
(a) Amount beneficially owned: See Row 9 of the cover page for each Reporting Person.
(b)Percent of class: See Row 11 of the cover page for each Reporting Person.
(c)Number of shares as to which the person has:
(i)Sole power to vote or to direct the vote: See Row 5 of the cover page for each Reporting Person.
(ii)Shared power to vote or to direct the vote: See Row 6 of the cover page for each Reporting Person.
(iii)Sole power to dispose or to direct the disposition of: See Row 7 of the cover page for each Reporting Person.
(iv)Shared power to dispose or to direct the disposition of: See Row 8 of the cover page for each Reporting Person.
Instruction. For computations regarding securities which represent a right to acquire an underlying security see §240.13d-3(d)(1).
Item 5. Ownership of Five Percent or Less of a Class.
If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following x*.
Instruction. Dissolution of a group requires a response to this item.
*Ana Parker has ceased to be the beneficial owner of more than five percent of the class of securities. Michael Parker continues to be the beneficial owner of more than five percent of the class of securities.
Item 6. Ownership of More than Five Percent on Behalf of Another Person.
Not applicable
Item 7. Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on By the Parent Holding Company.
Not applicable
Item 8. Identification and Classification of Members of the Group.
Not applicable
Item 9. Notice of Dissolution of Group.
Not applicable
CUSIP No. 003939W 109 | SCHEDULE 13G | Page 6 of 8 Pages |
Item 10. Certification.
(a)The following certification shall be included if the statement is filed pursuant to §240.13d-1(b):
By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under § 240.14a-11.
(b)The following certification shall be included if the statement is filed pursuant to §240.13d-1(c):
By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under § 240.14a-11.
SIGNATURE
After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.
Dated: January 21, 2021
/s /Michael Parker/s / Ana Parker
SignatureSignature
Michael ParkerAna Parker
Name/TitleName/Title
The original statement shall be signed by each person on whose behalf the statement is filed or his authorized representative. If the statement is signed on behalf of a person by his authorized representative other than an executive officer or general partner of the filing person, evidence of the representative's authority to sign on behalf of such person shall be filed with the statement, Provided, however, That a power of attorney for this purpose which is already on file with the Commission may be incorporated by reference. The name and any title of each person who signs the statement shall be typed or printed beneath his signature.
EXHIBIT
Exhibit I Joint Filing Agreement, dated January 21, 2021, among the signatories to this Schedule 13G.
CUSIP No. 003939W 109 | SCHEDULE 13G | Page 7 of 8 Pages |
APPENDIX A
Michael Parker owns outright 1,380,891 shares of Common Stock. He also is the sole manager of Tungsten III LLC, which owns outright 5,000,000 shares of Common Stock, and as a result, Mr. Parker may be deemed to be the beneficial owner of these shares. Mr. Parker also is the spouse of Ana Parker, who owns outright 9,086,939 shares. Because Mr. Parker shares with Mrs. Parker the voting and dispositive power over these 9,086,939 shares, Mr. Parker may be deemed to be the beneficial owner of these shares as well. As a result, Mr. Parker may be deemed to be the beneficial owner of a total of 15,467,830 shares.
Ana Parker owns outright 9,086,939 shares over which she shares voting and dispositive power with her spouse, Michael Parker. Mrs. Parker disclaims any beneficial ownership of any shares owned by Mr. Parker outright or over which Mr. Parker has voting or dispositive power. Mrs. Parker disclaims any beneficial ownership of any of the 1,583,333 shares of Common Stock that may be acquired upon the exercise of Series E Warrants (which expire May 26, 2021) held by her, any of the 600,000 shares of Common Stock that may be acquired upon the exercise of Series G Warrants (which expire July 2, 2023) held by her, any of the 1,230,769 shares of Common Stock that may be acquired upon the exercise of Series H Warrants (which expire May 14, 2024) held by her, any of the 3,428,571 shares of Common Stock that may be acquired upon the exercise of Series I Warrants (which expire October 18, 2024) held by her, or any of the 3,375,000 shares of Common Stock that may be acquired upon the exercise of Series J Warrants (which expire December 4, 2022) held by her, as all such warrants cannot be exercised until such time as the holder would not beneficially own, after such exercise, more than 4.9% of the outstanding shares of Common Stock; provided, however, that the holder may waive such ownership limitation, in which case such waiver will become effective sixty-one (61) days after the holder's delivery of such waiver notice. As of the date of this Schedule 13G, such limitation has not been waived as to any outstanding warrants.
The percentage ownership figures used in this filing are based on the most recently reported figure for outstanding shares contained in the Company's 10-K filed on December 11, 2020, which indicated that the total number of outstanding shares of Common Stock as of December 10, 2020 was 193,044,766.
CUSIP No. 003939W 109 | SCHEDULE 13G | Page 8 of 8 Pages |
Exhibit I
JOINT FILING AGREEMENT
PURSUANT TO RULE 13d-1(f)(1)
The undersigned acknowledge and agree that the foregoing statement on Schedule 13G is filed on behalf of each of the undersigned and that all subsequent amendments to this statement on Schedule 13G shall be filed on behalf of each of the undersigned without the necessity of filing additional joint filing agreements. The undersigned acknowledge that each shall be responsible for the timely filing of such amendments, and for the completeness and accuracy of the information concerning it contained therein, but shall not be responsible for the completeness and accuracy of the information concerning the others, except to the extent that it knows or has reason to believe that such information is inaccurate. This Agreement may be executed in any number of counterparts and all of such counterparts taken together shall constitute one and the same instrument.
Dated: January 21, 2021
/s /Michael Parker/s / Ana Parker
SignatureSignature
Michael ParkerAna Parker
Name/TitleName/Title